SIREN : 422669481
CURE-EMBALLAGES is a French company founded 27 years ago, specialized in the sector Fabrication d'emballages en bois. Based in BRAZEY-EN-PLAINE (21470), this company of category PME shows in 2025 a revenue of 6.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 852 029 € | 1 788 249 € | 7 092 460 € | 8 285 176 € | N/C | 4 002 030 € | 4 032 394 € | 3 736 346 € | 3 520 992 € |
| Net income | 483 € | 62 969 € | 487 349 € | 654 450 € | 232 184 € | 132 089 € | 97 101 € | 80 245 € | 85 425 € |
| EBITDA | 67 841 € | 85 360 € | 696 008 € | 956 429 € | N/C | 212 361 € | 135 697 € | 145 300 € | 151 336 € |
| Net margin | 0.0% | 3.5% | 6.9% | 7.9% | N/C | 3.3% | 2.4% | 2.1% | 2.4% |
In 2025, CURE-EMBALLAGES achieves revenue of 6.9 M€. Over the period 2017-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +8.7%. Vs 2024, growth of +283% (1.8 M€ -> 6.9 M€). After deducting consumption (4.6 M€), gross margin stands at 2.3 M€, i.e. a rate of 33%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 68 k€, representing 1.0% of revenue. Warning negative scissor effect: despite revenue change (+283%), EBITDA varies by -21%, reducing margin by 3.8 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 483 €, i.e. 0.0% of revenue. This profit can be retained or distributed to shareholders.
6 852 029 €
2 275 476 €
67 841 €
8 114 €
483 €
1.0%
The debt ratio (= Financial debt / Equity x 100) stands at 19%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 57%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.4 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 0.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
19.022%
56.849%
0.824%
5.435
16.0%
In 2025, the debt ratio of CURE-EMBALLAGES (19.02) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2025, the financial autonomy of CURE-EMBALLAGES (56.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of CURE-EMBALLAGES (5.43) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 250.35. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 17.4x. Operating income very largely covers interest expenses: high safety margin.
250.347
17.404
In 2025, the liquidity ratio of CURE-EMBALLAGES (250.35) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of CURE-EMBALLAGES (17.4x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 50 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 42 days. The company must finance 8 days of gap between collections and payments. Inventory turnover is 35 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 96 days of revenue, i.e. 1.8 M€ to permanently finance. Over 2017-2025, WCR increased by +144%, requiring additional financing.
1 826 408 €
50 j
42 j
35 j
96 j
Indicative estimate only : the number of comparable transactions in this sector is limited (44 transactions). This range of 194 079€ to 547 663€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 44 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CURE-EMBALLAGES with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication d'emballages en bois
The revenue of CURE-EMBALLAGES in 2025 is 6.9 M€.
Yes, CURE-EMBALLAGES generated a net profit of 483€ in 2025.
The headquarters of CURE-EMBALLAGES is located in BRAZEY-EN-PLAINE (21470), in the department Cote-d'Or.
The tax return of CURE-EMBALLAGES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CURE-EMBALLAGES operates in the sector Fabrication d'emballages en bois (NAF code 16.24Z). See the 'Sector positioning' section above to compare the company with its competitors.